Objective: To further understand the glucose metabolism and glycolytic pathway of obesity-driven ovarian cancer, the effect of glucose and the glycolytic pathway on cellular proliferation and expression of key targets of AMP-activated protein kinase(AMPK) and its potential role as a cell cycle regulator in ovarian cancer cells were investigated.Methods: Three ovarian cancer cell lines were used: SKOV3,Hey, and IGROV1.Cellular proliferation was assessed by MTT assay after exposure to different concentrations of glucose,metformin, glycolysis inhibitors [2-deoxyglucose (2-DG),3-bromopyruvate (3-BP)], transaminases inhibitor [aminooxyacetate (AOA)], glutamine, and pyuvate.Lactate, ATP, and glucose productions were assessed after treating the cells with glucose and glycolysis inhibitors.Cell cycle progression was evaluated via cellometer assay.Apoptosis was assessed using the Annexin Ⅴ-FITC assay.Phospho-AMPK and Pan-AMPK levels were assessed by Western blot to determine the expression of the downstream targets phospho-AMPK and ribosomal protein S6, cyclin E, cyclin D, p21, and p27 after treatment of cells with different concentrations of glucose and Compound C, a specific inhibitor of AMPK.